"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 11 | 11 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 10 | 10 |
| 2001 | 0 | 13 | 13 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 19 | 19 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 14 | 14 |
| 2007 | 0 | 20 | 20 |
| 2008 | 0 | 32 | 32 |
| 2009 | 0 | 25 | 25 |
| 2010 | 0 | 25 | 25 |
| 2011 | 0 | 33 | 33 |
| 2012 | 1 | 35 | 36 |
| 2013 | 0 | 39 | 39 |
| 2014 | 0 | 48 | 48 |
| 2015 | 0 | 52 | 52 |
| 2016 | 0 | 61 | 61 |
| 2017 | 0 | 60 | 60 |
| 2018 | 1 | 43 | 44 |
| 2019 | 0 | 34 | 34 |
| 2020 | 0 | 26 | 26 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 9 | 9 |
| 2024 | 0 | 10 | 10 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Characterization of chemoresistant cell populations improves risk stratification and therapy prediction in pediatric acute myeloid leukemia. Nat Commun. 2026 Oct 02; 17(1).
-
Outcomes of Children With Orbital Rhabdomyosarcoma, 1991-2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatr Blood Cancer. 2026 10; 73(10):e70613.
-
Oncologic outcomes of parenchyma-sparing resection for hepatoblastoma. J Pediatr Surg. 2026 Aug; 61(8):163195.
-
Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience. J Pediatr Hematol Oncol. 2026 Aug 01; 48(6):261-269.
-
Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431. Pediatr Blood Cancer. 2026 Jun; 73(6):e70293.
-
Sentinel lymph node status and oncological outcomes of high-risk and low-risk cutaneous primary melanoma. World J Surg Oncol. 2026 Mar 13; 24(1).
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma. J Gastrointest Surg. 2026 01; 30(1):102275.
-
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 06; 100(6):980-986.
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.